FDA approves first treatment to grant infants protection against RSV

Key Facts

• | AstraZeneca via AP Photo The FDA approved the first antibody designed to give babies protection against respiratory syncytial virus during their first year of life.
• Beyfortus, known as nirsevimab and developed by Sanofi and AstraZeneca, is a single injection of antibodies against the RSV virus.
• The FDA also cleared the antibody for children up to 24 months who are at risk of developing severe disease.
• The FDA is also reviewing an RSV vaccine for pregnant individuals who could pass on immunity to their babies, and the agency is slated to make a decision next month.

Click To Read Full Article